Cachexia therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1075504

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cachexia is a major side effect of cancer, resulting in significant muscle wasting, fat loss and organ failure. Up to 80% of cancer patients suffer and 25% succumb to this condition. This significantly affects the treatment regimens of cancer patients and affects their quality of life. We have developed monoclonal antibodies that block and reverse cachexia in preclinical mouse cancer models. Our aims are to humanise the antibody and manufacture it for the first clinical trial in humans.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2016

Funding Scheme: Development Grants

Funding Amount: $764,132.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Molecular Engineering of Nucleic Acids and Proteins

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biotechnology | cachexia | clinical trial | muscle wasting | therapeutic antibodies

Related Links